Volunteer, Malaria Case Management Analyst

Recruitment Team

Malaria is one of the leading causes of illness, death, and lost economic productivity in sub-Saharan Africa. While the scale-up of malaria control efforts has in many places resulted in significant reductions of malaria morbidity and mortality rates, malaria still claimed an estimated 660,000 lives in 2010. The majority of these deaths were among children under-five and pregnant women[1]. Continuing to reduce the burden of disease will require further increases in access to critical prevention tools, such as insecticide-treated nets, and increasing access to and uptake of high-quality diagnostic tests and treatments. In most sub-Saharan African countries, less than 20%[2] of people with suspected malaria receive a laboratory-confirmed diagnosis and less than 50%[3] of those receiving an antimalarial for uncomplicated malaria use a recommended artemisinin-based combination therapy (ACT)[4].



To achieve the Roll Back Malaria (RBM) Partnership's[5] goal of near zero-deaths from malaria by 2015, the key barriers that restrict access to recommended diagnostics and treatments for malaria must be overcome. Not only will this dramatically reduce the number of malaria-related deaths in the immediate future, it will also move countries towards elimination of the disease in the long run. The Clinton Health Access Initiative (CHAI) work will focus on activities that achieve the greatest possible impact in terms of reducing malaria mortality and attaining value for money. There is growing consensus that for greater health impact, cost-effective management of malaria, and accurate understanding of true burden